PMID- 11762330
OWN - NLM
STAT- MEDLINE
DCOM- 20020514
LR  - 20190815
IS  - 0142-9612 (Print)
IS  - 0142-9612 (Linking)
VI  - 23
IP  - 2
DP  - 2002 Jan
TI  - Blood-compatible biomaterials by surface coating with a novel 
      antithrombin-heparin covalent complex.
PG  - 527-35
AB  - Covalent antithrombin-heparin complex (ATH) was covalently grafted to a 
      polycarbonate urethane (Corethane) endoluminal graft (a kind gift of Corvita 
      Corporation) after being activated using 0.3% m/m NaOCl in 0.15 M phosphate pH 
      6.0. ATH graft density (1.98 x 10(-7) mol/m2) was 6 times the maximum amount of 
      unfractionated heparin (UFH) that could be bound to polycarbonate urethane 
      surfaces. Surface-bound ATH could be stored in sterile 0.15 M NaCl at 4 degrees C 
      for at least 2 months with good antithrombotic activity before being implanted 
      into rabbits. Analysis of ATH-coated tubing showed that it contained significant 
      direct thrombin inhibitory activity. In vivo testing in a rabbit model was 
      compared to non-activated non-coated surfaces, activated-non-coated surfaces, 
      hirudin-coated surfaces and antithrombin (AT)-coated surfaces. The weight of the 
      clot generated in the ATH-coated graft tubing was significantly less than the 
      weight of the clot generated within the hirudin-coated graft (p = 0.03 with a 
      1-tailed Student's t test). The anticoagulant nature of ATH grafts in vivo was 
      shown to be due to bound ATH because boththe AT-coated surfaces and non-coated 
      but activated surfaces showed similar thromboresistant efficacy to that of 
      untreated material (ANOVA; p < 0.05). Apart from the direct antithrombin activity 
      that contributed to much of the prolonged patency in vivo, surface-bound ATH 
      likely catalyzed AT inhibition of thrombin, as evidenced by a significant number 
      of 125I-AT binding sites (> or = 1.5 x 10(-8) mol/m2). Thus, ATH appears to be a 
      good candidate for coating cardiovascular devices, such as endoluminal grafts, 
      with high levels of substitution and significant long-term blood-compatibility.
FAU - Klement, P
AU  - Klement P
AD  - The Hamilton Clinic Hospitals Research Centre of The Hospital for Sick Children, 
      Toronto, Ont., Canada.
FAU - Du, Y J
AU  - Du YJ
FAU - Berry, L
AU  - Berry L
FAU - Andrew, M
AU  - Andrew M
FAU - Chan, A K C
AU  - Chan AK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (Antithrombins)
RN  - 0 (Biocompatible Materials)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Animals
MH  - Antithrombins/*chemistry
MH  - *Biocompatible Materials
MH  - *Blood
MH  - Heparin/*chemistry
MH  - Male
MH  - Rabbits
MH  - Surface Properties
EDAT- 2002/01/05 10:00
MHDA- 2002/05/15 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/05/15 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
AID - S0142-9612(01)00135-1 [pii]
AID - 10.1016/s0142-9612(01)00135-1 [doi]
PST - ppublish
SO  - Biomaterials. 2002 Jan;23(2):527-35. doi: 10.1016/s0142-9612(01)00135-1.